GT Apeiron Announces Enrollment of First Patient in Phase 1/2 “ELUCIDATE” Clinical…
- Preclinical data from AI-optimized GTAEXS617 support potential for improved therapeutic index compared to other CDK7 inhibitors under development - - Parallel translational initiative to…